Mounjaro and GPs: who prescribes it, and how the system actually works

What NICE TA1026 actually says GPs can and cannot do

The foundation for GP prescribing of tirzepatide is NICE Technology Appraisal 1026, published in December 2024. It recommends tirzepatide for adults with a BMI of 35 or above, alongside at least one weight-related condition such as high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease or type 2 diabetes. For people of South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, those thresholds are set 2.5 kg/m² lower under the appraisal.

Crucially, the guidance is phased. The first cohort — adults with a BMI of 40 or above plus four or more of those conditions — became eligible in June 2025. A second cohort, covering BMI 35–39.9 with four or more conditions, was activated in June 2026. Further cohorts are scheduled into 2027. That means a GP who wants to prescribe is currently constrained to patients who fit whichever phase is active at the time they consult. If you fall outside those parameters, an NHS prescription is not yet available from your surgery, even if a prescriber privately thinks you would benefit.

There is a further practical point. GP participation is voluntary under the 2026/27 QOF contract, so whether your practice has opted in varies by surgery and by area. The picture of which GPs are prescribing Mounjaro across England is therefore patchy rather than uniform. Checking with your own practice is still the only reliable way to know where you stand locally.

The trial data that shaped the guidance

NICE's recommendation did not appear in a vacuum. It was built substantially on SURMOUNT-1, the pivotal phase 3 trial involving 2,539 adults with obesity and no diabetes, published in the New England Journal of Medicine. At the highest 15mg dose over 72 weeks, participants lost an average of around 20–21% of body weight, with some analyses reaching approximately 22.5%. Those are headline figures and the trial population had specific characteristics, so a prescriber will not promise any individual that outcome. What the data gave NICE was enough confidence to recommend tirzepatide as a cost-effective option within NHS criteria, and enough confidence that the benefit-risk balance supports broader prescribing.

For context on what the evidence means alongside a GP consultation, it is worth reading NHS England's guidance on weight-management injections, which sets out what a GP should discuss, including lifestyle support, contraception interactions and the expectation that progress is reviewed at six months. If less than 5% weight loss is achieved at the highest tolerated dose by that point, the guidance says continuation should be reconsidered. That is a clinical conversation, not an automatic stop, but patients starting treatment through any route should know it forms part of the framework.

Private prescribing from a GP versus an online pharmacy

Not every GP is willing to prescribe tirzepatide privately, even for patients who do not qualify for the NHS route. Some practices have a blanket policy against it; others do it case by case. If you are looking at the private route, a GP private prescription for Mounjaro and a prescription from a GPhC-registered online pharmacy are both legally valid under UK law, provided a qualified prescriber makes the clinical decision. The prescriber does not have to work in a surgery.

There is a practical difference in how each works. A GP appointment may mean a wait of days or weeks depending on your surgery's availability. (If you are trying to get started in January, after the holidays, or want to time your first order for a particular point in the month, that wait matters.) A regulated online pharmacy can typically move faster, at nume, consultations are reviewed by a GPhC-registered Independent Prescriber, not software, on the same day, and treatment is dispatched the same day for next-working-day delivery if the order arrives before 12pm. The clinical bar is the same either way: a prescriber assesses your full picture before anything is issued. You can see how tirzepatide is priced privately on our treatment information page, where the full what-is-included breakdown lives.

For a broader picture of the tirzepatide eligibility criteria that apply on both NHS and private routes, the tirzepatide overview covers the licensed BMI thresholds, weight-related conditions and the clinical factors that a prescriber weighs up before approving treatment.

What this means if your GP has said no, or not yet

Being told you do not qualify on the NHS (yet) does not mean you are categorically unsuitable for treatment. The NHS criteria are designed around public-health prioritisation and cost-effectiveness at population level; the licensed eligibility for Mounjaro as a private prescription is somewhat broader. Adults with a BMI of 27 or above, with at least one weight-related condition, fall within the licence, and that assessment is made by the prescriber reviewing your individual case.

It is worth understanding the difference between "the NHS does not fund this for you right now" and "a prescriber cannot prescribe this for you". They are not the same thing. If you want to explore the route to Mounjaro without a traditional GP referral, a regulated online pharmacy is the established private pathway. The consultation covers the same ground a GP would cover: your weight, health history, any medicines you take, and whether there are contraindications. A prescriber who is not satisfied will not issue a prescription; that is what clinical assessment means.

If you are ready to find out whether treatment is right for you, our prescribers are here. Start your free consultation and have your questions answered the same day.